Diabetes Care review weighs oral semaglutide's kidney evidence and limits
The November commentary examines what is known about renal outcomes with the oral GLP-1 formulation and where the data remain thin.
MH
By Maren Holt · Senior Reporter, GLP-1
Oct 20 19:00 ETSource: Diabetes care
The wire
- 01A review article in Diabetes Care assesses oral semaglutide's promise and limitations for kidney outcomes.
- 02Clinicians treating type 2 diabetes with chronic kidney disease are weighing oral versus injectable GLP-1 options.
- 03Only the title and citation details are reported here; the underlying evidence and conclusions are in the full text.
From the source
Read at pubmed.ncbi.nlm.nih.govOral Semaglutide and the Kidney: Promise, Limitations, and the Road Ahead
Diabetes care · 2026 Nov 1 · Ma W, Xia F, Tao D et al.
Source URL https://pubmed.ncbi.nlm.nih.gov/42900811/
